10x Genomics (TXG) Receivables - Other (2024 - 2026)

10x Genomics has disclosed Receivables - Other across 3 years of filings, most recently posting $17.1 million for Q1 2026.

• Receivables - Other for Q1 2026 came in at $17.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $17.1 million (changed N/A YoY), and the FY2025 annual result was $35.5 million, up 5754.79% from the prior year.
• Receivables - Other came in at $17.1 million for Q1 2026 at 10x Genomics, down from $35.5 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $69.1 million in Q2 2025 to a low of $606000.0 in Q4 2024.
• The 3-year median for Receivables - Other is $35.5 million (2025), against an average of $35.0 million.
• Peak annual rise in Receivables - Other reached 5754.79% in 2025, while the deepest fall reached 5754.79% in 2025.
• 10x Genomics' Receivables - Other stood at $606000.0 in 2024, then soared by 5754.79% to $35.5 million in 2025, then tumbled by 51.79% to $17.1 million in 2026.
• The last three Receivables - Other figures came in at $17.1 million (Q1 2026), $35.5 million (Q4 2025), and $52.8 million (Q3 2025), per Business Quant data.